As of November 6, 2026, Lineage Cell Therapeutics Inc is a publicly traded company (NYSE: LCTX). The largest holder reporting an active stake on Schedule 13D is Broadwood Partners, L.P., at 23.1%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include BlackRock (5.3%), Chernett Jorey (5%) (Schedule 13D/A, November 14, 2025).
Is this your company?
About to sign with, pay or invest in Lineage Cell Therapeutics Inc? See the free Snapshot first.
Free to see. No signup.
Is Lineage Cell Therapeutics Inc a real, registered company?
- Lineage Cell Therapeutics Inc files with the SEC under CIK 876343 (its SEC filings).
- Its shares are listed under the ticker LCTX on NYSE (SEC company record).
- Incorporated in California; business address in Carlsbad, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Lineage Cell Therapeutics Inc in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-07-29).
Who are Lineage Cell Therapeutics Inc's owners and officers?
Lineage Cell Therapeutics Inc: incorporated in California; business address in Carlsbad, California; industry Biological Products, (No Diagnostic Substances) (Schedule 13G, 2026-07-29).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-07-29 | Blackrock, Inc. | 5.3% |
| Schedule 13D/A, 2025-11-14 | Broadwood Partners, L.P. | 23.1% |
| Schedule 13G, 2025-09-26 | Chernett Jorey | 5% |
| Schedule 13G/A, 2025-07-17 | Blackrock, Inc. | 1% |
Questions about who owns Lineage Cell Therapeutics Inc
Who owns Lineage Cell Therapeutics Inc?
On this page, 3 holders' latest ownership filings report 5% or more of Lineage Cell Therapeutics Inc: Broadwood Partners, L.P. (23.1%, Schedule 13D/A, filed 2025-11-14), Blackrock, Inc. (5.3%, Schedule 13G, filed 2026-07-29) and Chernett Jorey (5%, Schedule 13G, filed 2025-09-26).
Who are the largest shareholders of Lineage Cell Therapeutics Inc?
By the share each holder's latest filing reports, the largest holders of Lineage Cell Therapeutics Inc on this page are Broadwood Partners, L.P. (23.1%), Blackrock, Inc. (5.3%) and Chernett Jorey (5%).
When did Broadwood Partners, L.P. buy into Lineage Cell Therapeutics Inc?
The filings give report dates, not purchase dates. The earliest filing from Broadwood Partners, L.P. on this page is the Schedule 13D/A, filed 2025-11-14, reporting 23.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Lineage Cell Therapeutics Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Lineage Cell Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lineage Cell Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Lineage Cell Therapeutics Inc shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Broadwood Capital Inc., a 10% owner: 99,209,612 shares (39.2% of shares outstanding), 49,648,620 held directly and 49,560,992 indirectly, on a joint filing (Form 4, 2025-01-28).
- Broadwood Partners, L.P., a director and 10% owner: 99,209,612 shares (39.2% of shares outstanding), 49,648,620 held directly and 49,560,992 indirectly, on a joint filing (Form 4, 2025-01-28).
- , a director and 10% owner: 99,209,612 shares (39.2% of shares outstanding), 49,648,620 held directly and 49,560,992 indirectly, on a joint filing (Form 4, 2025-01-28).
- , a director: 298,555 shares (0.12% of shares outstanding) (Form 4, 2024-11-25).
- , the chief executive and president: 255,516 shares (0.10% of shares outstanding) (Form 4, 2026-03-12).
Shares outstanding: 252,907,464 as of 2026-08-03, from the company's latest SEC cover page.
How much has Lineage Cell Therapeutics Inc raised?
No fundraising or offering filing from Lineage Cell Therapeutics Inc is on file with us.
Keep reading
More on Lineage Cell Therapeutics Inc and the records around it.
Lineage Cell Therapeutics Inc elsewhere on the record
- 5%+ stake filings Jul 2026
Companies that share a holder
- BROADWOOD PARTNERS, L.P. also filed stake reports on 2 other companies: Insight Molecular Diagnostics Inc. (Apr 2026), STAAR SURGICAL CO (Mar 2026)
- Chernett Jorey also filed stake reports on 16 other companies: CVRx, Inc. (Oct 2026), WW INTERNATIONAL, INC. (Aug 2026), Neuronetics, Inc. (Aug 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/lineage-cell-therapeutics